TY - JOUR
KW - Buprenorphine/therapeutic use
KW - Buprenorphine, Naloxone Drug Combination/therapeutic use
KW - Female
KW - Humans
KW - Opioid-Related Disorders/drug therapy
KW - Pregnancy
AU - H. M. Link
AU - H. E. Jones
AU - L. A. Miller
AU - K. Kaltenbach
AU - N. S. Seligman
A1 - 
AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY; Maternal-Fetal Medicine Center, John R. Oishei Children's Hospital, Kaleida Health, 818 Ellicott St., Buffalo, NY 14203. Electronic address: hmlink@gmail.com.; Department of Obstetrics and Gynecology, University of North Carolina, Raleigh, NC.; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY.; Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA.; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY.
BT - American journal of obstetrics & gynecology MFM
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 5
CY - United States
DO - 10.1016/j.ajogmf.2021.100369
IS - 5
JF - American journal of obstetrics & gynecology MFM
LA - eng
M1 - Journal Article
PP - United States
PY - 2021
SN - 2589-9333; 2589-9333
SP - 100369
T1 - Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder
T2 - American journal of obstetrics & gynecology MFM
TI - Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 33831585
U3 - 10.1016/j.ajogmf.2021.100369
VL - 3
VO - 2589-9333; 2589-9333
Y1 - 2021
Y2 - Sep
ER -